Jason Hoitt - 15 Mar 2026 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Reporting relationship: Chief Patient Officer
Issuer ticker: STOK
Reported as of: 15 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Mar 2026, 17:26:50 UTC
Prior SEC filing: 19 Feb 2026
Next SEC filing: 19 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Allan, Attorney-in-Fact

Key filing fact

Jason Hoitt filed Form 4 for Stoke Therapeutics, Inc. (STOK) on 17 Mar 2026.

Key facts

This page summarizes Jason Hoitt's Form 4 filing for Stoke Therapeutics, Inc. (STOK).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Mar 2026, 17:26.

Change

Previous filing in this sequence was filed on 19 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001762572 Primary reporting owner

Hoitt Jason

Relationship: Chief Patient Officer
Address: C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD
Signature: /s/ Jonathan Allan, Attorney-in-Fact
Signature date: 17 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

STOK transaction

Common Stock

Options Exercise

Transaction value
Shares: +10,000
Change %: +251%
Price: $0.000000^*
Shares after: 13,988
Date: 15 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

STOK transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -10,000
Change %: -25%
Price: $0.000000^*
Shares after: 30,000
Date: 15 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The reported total includes an aggregate 2,186 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d).

Footnote F2

Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.

Footnote F3

The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.